Cargando…
The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021
BACKGROUND: Cardiometabolic disease is a clinical syndrome characterized by multiple metabolic disorders, with atherosclerosis as the core and cardiovascular and cerebrovascular events as the outcome. Drug research and development (R&D) in cardiometabolic diseases has grown rapidly worldwide. Ho...
Autores principales: | Li, Chen, Hao, Jun, Zheng, Yitian, Wang, Chuangshi, Yang, Jie, Wang, Wenyao, Zhang, Kuo, Shao, Chunli, Hui, Wen, Wang, Jiancheng, Li, Wei, Tang, Yi-Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067219/ https://www.ncbi.nlm.nih.gov/pubmed/37005689 http://dx.doi.org/10.1186/s13098-023-01043-8 |
Ejemplares similares
-
Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009–2022
por: Li, Chen, et al.
Publicado: (2023) -
Level of evidence supporting the Chinese cardiovascular disease clinical practice guidelines and its evolution in the past two decades
por: Li, Chen, et al.
Publicado: (2023) -
Atherogenic index of plasma for non-diabetic, coronary artery disease patients after percutaneous coronary intervention: a prospective study of the long-term outcomes in China
por: Zheng, Yitian, et al.
Publicado: (2022) -
The Impact of the Triglyceride-Glucose Index on Poor Prognosis in NonDiabetic Patients Undergoing Percutaneous Coronary Intervention
por: Yang, Jie, et al.
Publicado: (2021) -
Elevated HsCRP in Chronic Obstructive Pulmonary Disease: A Prospective Study of Long-Term Outcomes After Percutaneous Coronary Intervention
por: Zheng, Yitian, et al.
Publicado: (2022)